Page 4 - Athersys Inc News Today

The global regenerative medicine market is experiencing significant growth, attributable to the high adoption of stem cell technology, the increase in the usage of nanotechnology, the rise in chronic diseases and trauma emergencies, and recent developments in the field of medical equipment technology.Wilmington, Delaware, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Allied Market Research recently published a report, titled, “Regenerative Medicine Market by Product Type (Gene Therapy, Cell Therapy, ...

Anti-aging Therapeutics Market worth $ 2013.5 Million by 2030 – Exclusive Report by InsightAce Analytic

Analysts’ new coverage for Sunday, November 12th: StockNews.com initiated coverage on shares of ARCA biopharma (NASDAQ:ABIO). StockNews.com issued a sell rating on the stock. StockNews.com started coverage on shares of American Equity Investment Life (NYSE:AEL). StockNews.com issued a hold rating on the stock. StockNews.com started coverage on shares of Aethlon Medical (NASDAQ:AEMD). The firm issued […]

The cell therapy market size is forecasted to increase by USD 21.061 billion from 2021 to 2026, at a CAGR of 56.79%, according to the recent market study by Technavio. The growth of the market will be driven by the increasing prevalence of chronic diseases, limitations in traditional organ transplantations fueling demand for cell therapies, and increasing funding in cell-based research. North America will account for 40% of the market growth during the forecast period. The growth of the regional

/PRNewswire/ -- The cell therapy market size is forecasted to increase by USD 21.061 billion from 2021 to 2026, at a CAGR of 56.79%, according to the recent...

Item3.01Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing As previously disclosed, Athersys, Inc. received a written notice...

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX), (“Athersys” or the “Company”) a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announces it has entered into a warrant exercise inducement offer letter to raise gross proceeds of up to appr...

Athersys, Inc. (NASDAQ:ATHX – Get Free Report) was the target of a significant increase in short interest in September. As of September 30th, there was short interest totalling 993,200 shares, an increase of 25.2% from the September 15th total of 793,500 shares. Based on an average trading volume of 759,600 shares, the days-to-cover ratio is […]

Athersys, Inc. , a cell therapy and regenerative medicine company developing MultiStem® for critical care indications, announces it has entered into a warrant exercise inducement offer letter to...

StockNews.com initiated coverage on shares of Athersys (NASDAQ:ATHX – Free Report) in a research report sent to investors on Wednesday. The firm issued a hold rating on the biopharmaceutical company’s stock. Athersys Stock Performance Shares of NASDAQ ATHX opened at $0.10 on Wednesday. Athersys has a 1 year low of $0.10 and a 1 year […]